Mater Private Network First to Use Cutting-Edge Global AFib Technology in Ireland

Mater Private Network is proud to announce the successful integration of the cutting-edge FARAVIEW™ Software, utilised in the treatment of Atrial fibrillation (AFib), to its Dublin centre of excellence. As one of just seven centres granted early access to this revolutionary technology under limited market release, Mater Private Network is driving the future of cardiac care in Ireland, benefiting hundreds of patients nationwide.

This milestone follows Mater Private Network’s selection as one of only three centres globally to take part in the FARAVIEW technology study into the treatment of AFib, highlighting the Network’s leadership in cardiac electrophysiology. Leading this initiative in Ireland are Prof. Gábor Széplaki, Head of Cardiac Electrophysiology, and Dr. Noel Fitzpatrick, Consultant Cardiologist at Mater Private Network in Dublin. Atrial fibrillation (AFib) is the most common irregular heart rhythm, with an estimated 8 million patients living with this condition in Europe, suffering from symptoms such as fatigue, palpitations and breathlessness, depending on the severity of the condition. Minimally invasive, innovative technologies such as the FARAPULSE Pulsed Field Ablation System may change the course of treatment for many in the future. 

Prof. Gábor Széplaki explains: “At Mater Private Network, we participate in trials of innovative new technology such as this, with the goal of setting new standards in Irish cardiac care and we are delighted with this result. The integration of FARAVIEW mapping with the FARAPULSE PFA System allows us to offer safer, faster, and more precise treatments for those suffering from AFib. As one of the few institutions with access to this cutting-edge development, this technology marks a new era in AFib care in Ireland. We are proud to be a part of that journey, ensuring our patients receive world-class, minimally invasive solutions that significantly improve their quality of life.”

Since adopting the FARAPULSE™ PFA System in 2022, the Electrophysiology team at Mater Private Network has treated over 1,400 patients, targeting cardiac tissue while preserving surrounding structures. The introduction of FARAVIEW™ integrated mapping enhances existing technologies, allowing for precise visualisation of the FARAWAVE NAV catheter on the OPAL HDx Mapping system. This system also reduces the need for X-ray exposure and improves procedural workflow, accuracy, and outcomes for patients.

During the pre-launch trial, the Mater Private Network team completed 10 cases under the NAVIGATE-PF Study. Completion of that first in men trial was required to get approval for the device from the competent authorities in the US and Europe. Globally, over 200,000 cases of AFib have been treated with FARAPULSE PFA, including 2,100 FARAVIEW cases in the USA.